CRISPR Therapeutics AG

Historical 13F Holders

Symbol
CRSP
CUSIP
H17182108
All holders as of
Q2 2026
Type
Equity
Class
NAMEN AKT
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for H17182108 since 12/18/2024, newest first.

Filer % of Class Filed
Orbis Investment Management Ltd 13G/A Amendment 3
5.6% 8/14/2026
Event 6/30/2026
BlackRock, Inc. 13G/A Amendment 1 8.3% 7/27/2026
Event 6/30/2026
Orbis Investment Management Ltd 13G/A Amendment 2
6.3% 5/15/2026
Event 3/31/2026
Capital World Investors 13G 5.1% 5/14/2026
Event 3/31/2026
ARK Investment Management LLC 13G/A Amendment 13
11.8% 4/30/2026
Event 3/31/2026
Orbis Investment Management Ltd 13G/A Amendment 1
6.2% 2/17/2026
Event 12/31/2025
Capital International Investors 13G/A Amendment 4 1.2% 2/5/2026
Event 1/30/2026
Orbis Investment Management Ltd 13G
5.5% 11/14/2025
Event 9/30/2025
ARK Investment Management LLC 13G/A Amendment 12
10.8% 11/4/2025
Event 9/30/2025
BlackRock, Inc. 13G 6.9% 7/17/2025
Event 6/30/2025
ARK Investment Management LLC 13G/A Amendment 11
11.9% 5/14/2025
Event 3/31/2025
Capital International Investors 13G/A Amendment 3 7.4% 5/13/2025
Event 3/31/2025
ARK Investment Management LLC 13G/A Amendment 10 10.5% 2/14/2025
Event 12/31/2024
ARK Investment Management LLC 13G/A Amendment 9 8.8% 1/10/2025
Event 9/30/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 14 206 k $11.4 M
2026 Q2 566 81.7 M $5.57 B
2026 Q1 532 77.2 M $3.67 B
2025 Q4 530 78.4 M $4.11 B
2025 Q3 497 72.8 M $4.72 B
2025 Q2 489 72.8 M $3.54 B
2025 Q1 438 64.7 M $2.20 B
2024 Q4 444 64.6 M $2.54 B
2024 Q3 457 60.4 M $2.83 B
2024 Q2 495 60.5 M $3.27 B
2024 Q1 534 61.8 M $4.28 B
2023 Q4 530 56.6 M $3.54 B
2023 Q3 450 55.1 M $2.51 B
2023 Q2 463 54.8 M $3.07 B
2023 Q1 415 56.3 M $2.54 B
2022 Q4 435 57.6 M $2.60 B
2022 Q3 478 56.9 M $3.76 B
2022 Q2 475 55.7 M $3.40 B
2022 Q1 487 51.3 M $3.53 B
2021 Q4 488 43.5 M $3.34 B
2021 Q3 513 40.4 M $4.57 B
2021 Q2 551 40.7 M $6.62 B
2021 Q1 489 43.0 M $5.23 B
2020 Q4 459 47.5 M $7.32 B
2020 Q3 337 47.9 M $4.03 B
2020 Q2 309 39.3 M $2.93 B
2020 Q1 284 39.3 M $1.69 B
2019 Q4 282 31.7 M $1.93 B
2019 Q3 203 27.5 M $1.13 B
2019 Q2 210 27.8 M $1.31 B
2019 Q1 192 26.0 M $929 M
2018 Q4 173 22.1 M $632 M
2018 Q3 207 22.9 M $1.02 B
2018 Q2 194 18.7 M $1.10 B
2018 Q1 145 18.7 M $857 M
2017 Q4 88 12.5 M $293 M
2017 Q3 67 10.1 M $180 M
2017 Q2 42 9.70 M $155 M
2017 Q1 37 9.71 M $211 M
2016 Q4 27 9.84 M $198 M
2016 Q1 1 40.0 $1.00 k